Markets
TOPSHOT-FRANCE-TECHNOLOGY-POLITICS-GOVERNMENT-ECONOMY
Meta CEO Mark Zuckerberg speaks with Microsoft CEO Satya Nadella (Charles Platiau/Getty Images)

Morgan Stanley touts a $70 billion boost for megacap tech companies from the One Big Beautiful Bill Act

Tax tweaks are poised to give a huge lift to five of the Magnificent 7’s free cash flows — and they just might send that extra money to another member of the cohort!

Luke Kawa
7/22/25 2:47PM

Morgan Stanley has dotted its I’s and crossed its T’s to figure out just how much of a near-term boost the budget reconciliation bill dubbed the “One Big Beautiful Bill Act” will give to the cash flows of megacap tech companies.

TL;DR: a more than $70 billion improvement to this year’s free cash flow (that is, operating cash flow less capex) for Amazon, Alphabet, Meta, Microsoft, and Apple. If Morgan Stanleys estimates are in the ballpark, this would be the equivalent of adding more free cash flow than Meta generated in 2024 as a whole ($54 billion).

MSFCFTech

What’s fueling this?

  • 100% bonus depreciation on qualified property in its first year in service is restored;

  • Domestic R&D expenses are fully deductible the year they occur, along with allowing retroactive deductions for domestic R&D costs from 2022-24 that were deferred; and

  • Shifts to how foreign-derived earnings are taxed.

In a note titled “The Big Beautiful Tech Tax Bill,” Morgan Stanley’s team, led by Todd Castagno, suggests that the effects could begin showing up this quarter, while cautioning that the ultimate impact “could vary meaningfully.”

These tax tweaks are intended to spur investment. It’s unlikely that this is a major dial-mover on the hundreds of billions that tech companies are dead set on shelling out to enhance their AI footprints, but hey, it doesn’t hurt.

“Rather than altering core investment and capital return strategies, we think excess capital could be used for reinvestment in AI infrastructure and data centers or added strategic M&A flexibility,” the team wrote.

On the one hand, it’s nice to have more cash as you spend it hand over fist. On the other hand, it’s not like these companies aren’t mulling other options to access money for AI-related capex, and capital markets would likely be happy to finance any such endeavors.

More Markets

See all Markets
markets

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.